View Older Stories View More Recent Stories

Apr 4, 2016 08:09AM Portola Pharma (PTLA) Enters Andexanet Alfa Development Agreement with Daiichi Sankyo
Apr 4, 2016 08:00AM Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan
Mar 24, 2016 07:03AM Portola Pharma's (PTLA) Phase 3 APEX Missed Primary Efficacy Testing Threshold
Mar 24, 2016 07:00AM Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Mar 24, 2016 04:00AM Portola Pharmaceuticals to Hold Conference Call on Thursday, March 24, at 8:30 am ET
Mar 1, 2016 08:00AM Portola Pharmaceuticals to Present at Cowen and Company 36th Annual Health Care Conference
Feb 26, 2016 05:00AM Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
Feb 19, 2016 08:00AM Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, February 26
Feb 17, 2016 05:44PM Portola Pharma (PTLA) BLA for Andexanet Alfa Accepted for Review by FDA
Feb 17, 2016 05:42PM Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDA
Feb 1, 2016 06:56AM Portola Pharma (PTLA) Enters Licensing Agreements for Investigational Agent Andexanet in Japan (BMY) (PFE)
Feb 1, 2016 06:55AM Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Feb 1, 2016 06:55AM Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 Million
Jan 8, 2016 08:08AM Portola Pharma (PTLA) to Update on Regulatory, Commercial Milestones and Discovery Pipeline
Jan 8, 2016 08:00AM Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016
Dec 18, 2015 08:01AM Portola Pharma (PTLA) Announces Completion of Andexanet Alfa BLA Submission
Dec 18, 2015 08:00AM Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet Alfa
Dec 5, 2015 08:00AM Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematology Annual Meeting and Exposition
Nov 12, 2015 08:00AM Portola Pharmaceuticals to Host Analyst and Investor Day on November 19
Nov 11, 2015 10:45AM The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals’ Phase 3 ANNEXA Studies of Andexanet Alfa
Nov 9, 2015 04:05PM Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Nov 6, 2015 08:00AM Portola Pharmaceuticals Announces Phase 3 ANNEXA™-R Part 2 Study Results to be Presented at American Heart Association Scientific Sessions 2015
Nov 4, 2015 08:00AM Portola Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference
Nov 2, 2015 08:00AM Portola Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Monday, November 9
Oct 30, 2015 08:00AM Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Oct 13, 2015 08:00AM Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients
Sep 24, 2015 05:31PM Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors
Sep 15, 2015 08:00AM Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints
Sep 10, 2015 08:00AM Portola Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Aug 27, 2015 04:02PM Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015
Aug 27, 2015 04:02PM Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015
Aug 4, 2015 04:01PM Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Aug 4, 2015 04:01PM Portola Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Jul 28, 2015 08:00AM Portola Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4
Jul 28, 2015 08:00AM Portola Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Tuesday, August 4
Jun 24, 2015 02:30PM Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C
Jun 24, 2015 02:30PM Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect
Jun 15, 2015 08:00AM Portola Pharmaceuticals Appoints Industry Leader Tao Fu as Executive Vice President, Chief Commercial and Business Officer
Jun 9, 2015 04:00PM Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress
Jun 9, 2015 04:00PM Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress
Jun 3, 2015 08:00AM Portola Pharmaceuticals to Present at Goldman Sachs 36th Annual Global Healthcare Conference
May 29, 2015 07:58AM Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib
May 29, 2015 07:58AM Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib
May 18, 2015 08:00AM Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology (ASCO) Annual Meeting
May 6, 2015 04:01PM Portola Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
May 5, 2015 08:01AM Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
May 5, 2015 08:00AM Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
May 5, 2015 08:00AM Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference
View More Recent Stories View Older Stories